IP Library Granted Patent US 8,710,223
Granted Patent B2
US 8,710,223 · App. 13/188,222 · Granted Apr 29, 2014

Protein kinase C inhibitors and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,710,223
App. No.
13/188,222
Granted
Apr 29, 2014
Kind
B2
Abstract

This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Claims (3)

1. A compound of the formula:

N2-(4-Cyclopropyl-2-fluoro-5-tetrazol-1-yl-phenyl)-5-fluoro-N4-(2,2,6,6-tetramethyl-piperidin-4-yl)-pyrimidine-2,4-diamine (I-12), or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound of claim 1 , wherein the pharmaceutically acceptable salt is a formate salt.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2011
From: HOLLAND, SACHA; KOLLURI, RAO; ALVAREZ, SALVADOR; DUNCTON, MATTHEW; SINGH, RAJINDER; ZHANG, JING; MASUDA, ESTEBAN
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 027222/0604 →